Amneal Pharmaceuticals, Inc. (AMRX)

Market Cap	4.41B
Revenue (ttm)	2.93B +9.5%
Net Income	5.90M
EPS	0.02
Shares Out	314.36M
PE Ratio	872.54
Forward PE	16.65
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,844,774
Open	13.99
Previous Close	13.95
Day's Range	13.96 - 14.35
52-Week Range	6.69 - 14.66
Beta	1.35
Analysts	Buy
Price Target	13.25 (-5.56%)
Earnings Date	Feb 27, 2026

About AMRX

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalm...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 8,300
• Stock Exchange: NASDAQ
• Ticker Symbol: AMRX
• Website: https://www.amneal.com

Financial Performance

In 2024, Amneal Pharmaceuticals's revenue was $2.79 billion, an increase of 16.73% compared to the previous year's $2.39 billion. Losses were -$116.89 million, 39.2% more than in 2023.

Analyst Summary

According to 4 analysts, the average rating for AMRX stock is "Buy." The 12-month stock price target is $13.25, which is a decrease of -5.56% from the latest price.

Price Target

$13.25

(-5.56% downside)

Analyst Consensus: Buy